ReviewFrontiers in oncology2023
Pancreatic cancer and exosomes: role in progression, diagnosis, monitoring, and treatment.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Exosome-loaded nanoradiosensitizers in radiotherapy for preventing post-irradiation tumor recurrence: mechanisms, preclinical evidence, and translational challenges.Discover nano · 2026Review
- The updated role of exosomes in cancer diagnosis and therapy.Discover oncology · 2026Review
- Dual role of exosomes in pancreatic cancer: Underlying mechanisms and research advances (Review).Oncology letters · 2026Review
- Extracellular Vesicles in Pancreatic Cancer Function and Potential Clinical Applications.OncoTargets and therapy · 2026Review
- Comparison of therapeutic potential of macrophage- or mesenchymal stem cell-derived exosomes in pancreatic cancer: An updated review.World journal of stem cells · 2025Review
- Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma.Journal of personalized medicine · 2025Review
- Exosome-based approaches in cancer along with unlocking new insights into regeneration of cancer-prone tissues.Regenerative therapy · 2025Review
- Reciprocal Modulation of Tumour and Immune Cell Motility: Uncovering Dynamic Interplays and Therapeutic Approaches.Cancers · 2025Review
- Serum-derived exosomal miR-7977 combined with miR-451a as a potential biomarker for pancreatic ductal adenocarcinoma.BMC cancer · 2025Article
- Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.Journal of hematology & oncology · 2025Review
- Prospect of extracellular vesicles in tumor immunotherapy.Frontiers in immunology · 2025Review
- Targeting CSC-immune cell crosstalk to overcome chemoresistance and enhance immunotherapy efficacy.Frontiers in immunology · 2025Review
- Exosome applications for the diagnosis and treatment of pancreatic ductal adenocarcinoma: An update (Review).Oncology reports · 2025Review
- Application of Cord Blood-Derived Exosomes in Tumor Prevention and Treatment.Clinical Medicine Insights. Oncology · 2025Review
- Targeting cancer via macrophage-derived exosomal miRNAs: implications for tumor progression and resistance.Frontiers in immunology · 2025Review
- Proteome profiling of extracellular vesicles-derived from hepatitis B virus-infected hepatocellular carcinoma cell lines identifies PDCD11 as a carrier of viral RNAs.Frontiers in cell and developmental biology · 2025Article
- A novel tumor-derived exosomal gene signature predicts prognosis in patients with pancreatic cancer.Translational cancer research · 2024Article
- Effects of exosomes and inflammatory response on tumor: a bibliometrics study and visualization analysis via CiteSpace and VOSviewer.Journal of cancer research and clinical oncology · 2024Article
- Review
- Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer.Pharmacological reports : PR · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is one of the most dangerous diseases that threaten human life, and investigating the details affecting its progression or regression is particularly important. Exosomes are one of the derivatives produced from different cells, including tumor cells and other cells such as Tregs, M2 macrophages, and MDSCs, and can help tumor growth. These exosomes perform their actions by affecting the cells in the tumor microenvironment, such as pancreatic stellate cells (PSCs) that produce extracellular matrix (ECM) components and immune cells that are responsible for killing tumor cells. It has also been shown that pancreatic cancer cell (PCC)-derived exosomes at different stages carry molecules. Checking the presence of these molecules in the blood and other body fluids can help us in the early stage diagnosis and monitoring of PC. However, immune system cell-derived exosomes (IEXs) and mesenchymal stem cell (MSC)-derived exosomes can contribute to PC treatment. Immune cells produce exosomes as part of the mechanisms involved in the immune surveillance and tumor cell-killing phenomenon. Exosomes can be modified in such a way that their antitumor properties are enhanced. One of these methods is drug loading in exosomes, which can significantly increase the effectiveness of chemotherapy drugs. In general, exosomes form a complex intercellular communication network that plays a role in developing, progressing, diagnosing, monitoring, and treating pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.